Blog 3: What Happens to Muscle on a GLP-1?

An honest look at lean mass, training, and the research without overstating it

This is the question I get asked most often when the topic of GLP-1 medications comes up in the gym context, and it is the right question to ask. I want to give you an honest answer, which means I also have to be upfront about where the research is clear, where it is mixed, and where we are still waiting on better data.

What the Research Currently Shows

A 2025 systematic review and network meta-analysis published in the journal Metabolism (Karakasis et al., PMID: 39719170), which pooled data from 22 randomized controlled trials and 2,258 participants, found that lean mass loss comprised approximately 25 percent of total weight lost on average across GLP-1 receptor agonist studies.6 Estimates across different studies have ranged from roughly 20 to 40 percent depending on the medication, dose, population, and measurement approach used. The higher estimates tend to come from studies with faster weight loss rates and without structured resistance training or protein guidance built into the protocol.

A note on the evidence: The clinical significance of this lean mass change is actively debated. A 2024 commentary in JAMA (Conte, Hall, and Klein, JAMA 2024;332:9-10) raised the question of whether the lean mass loss observed in GLP-1 trials is clinically meaningful, noting that some of it may be proportional to overall weight reduction rather than representing disproportionate skeletal muscle loss. This debate is ongoing and the answer likely differs based on age, activity level, protein intake, and training status.

What I take from this is not panic, but it is not dismissal either. The signal is there. The degree to which it matters for an active person who is training consistently and eating adequate protein is a genuinely open question. And that is exactly why what you do while on these medications matters so much.

The Role of Resistance Training and Protein

I have spent the better part of 19 years in this industry watching how the body responds to different training and nutrition inputs during periods of caloric deficit. The principles are not new. What preserves muscle during weight loss, whether you are doing it through diet alone, with medication, or with any other intervention, is consistent resistance training and adequate protein intake. This is not specific to GLP-1 medications. It is a fundamental principle that applies across the entire weight loss literature.

A 2025 case series published in SAGE Open Medicine (Tinsley et al., PMID: 41122508) described three patients on semaglutide or tirzepatide who engaged in resistance training 3 to 5 days per week with protein intakes of approximately 0.73 to 1.04 grams per pound of fat-free mass.7 Their lean soft tissue outcomes ranged from a loss of 6.9 percent to a gain of 5.8 percent despite losing 13 to 33 percent of total body weight. I want to be clear that this is a case series of three people. You cannot draw definitive conclusions from that. But it supports the plausibility of the approach and is consistent with everything we know from the broader resistance training and protein literature.

A 2025 randomized controlled pilot trial (Binmahfoz et al., PMC12323239) found that incorporating resistance training into a dietary weight loss program preserved or enhanced muscle function without compromising fat loss outcomes.8 This trial was conducted in people losing weight through diet, not specifically through GLP-1 medication, which is an important distinction. The principle transfers, but the specific application in GLP-1 users still needs larger, longer-term RCT data.

The Docs Who Lift April 2026 episode Do GLP-1 Medicines Actually Cause Muscle Loss? New Research With Dr. Henning Langer, and their March 2026 BELIEVE trial episode with Dr. Stephen Heymsfield, both go deep into where the research currently stands and what the clinical approach looks like. Worth a full listen.

Practical Application

Here is how I think about this for our community. Evidence-based protein targets during active weight loss are approximately 1.2 to 1.6 grams per kilogram of body weight per day, distributed across meals with approximately 25 to 40 grams per eating occasion. This comes from the general weight loss research rather than from GLP-1-specific trials, because large RCTs examining protein intake specifically during GLP-1 treatment have not yet been published. What we do know is that GLP-1 medications significantly suppress appetite, which can unintentionally reduce protein intake if you are not actively prioritizing it. That is the primary risk.

The practical checklist is straightforward:

1. Keep training. 2 to 4 resistance sessions per week targeting major muscle groups is your most protective input.
2. Actively prioritize protein at every meal, especially when appetite suppression reduces your overall desire to eat.
3. Track strength progression, not just scale weight. If your lifts are holding or improving while your weight is decreasing, you are likely preserving the tissue that matters most.
4. Communicate with your prescribing physician if side effects are significantly interfering with your ability to eat or train. Dose adjustments exist for a reason.

Blog 3: Sources

1. Docs Who Lift: Do GLP-1 Medicines Actually Cause Muscle Loss? New Research With Dr. Henning Langer. April 14, 2026. docswholift.com
2. Docs Who Lift: Bimagrumab and Semaglutide: The BELIEVE Trial Results With Dr. Stephen Heymsfield. March 23, 2026. docswholift.com
3. Docs Who Lift: Are GLP-1 Medicines Shredding Your Bones? With Dr. Susan Brian. May 18, 2026. docswholift.com
4. Docs Who Lift: How Often Should You Really Lift Weights? Feat. Dr. Stuart Phillips. April 2, 2026. docswholift.com
5. 6. Karakasis P et al. GLP-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113. PMID: 39719170.
6. 7. Tinsley GM et al. Preservation of lean soft tissue during weight loss on GLP-1 and GLP-1/GIP receptor agonists: Case series (n=3). SAGE Open Med. 2025. PMID: 41122508. [Preliminary; not a controlled trial.]
7. 8. Binmahfoz A et al. Home-based resistance training during dietary weight loss: randomised controlled pilot trial. Nutr Metab. 2025. PMC12323239. [Conducted in dietary weight loss context, not GLP-1 users specifically.]
8. Conte C, Hall KD, Klein S. Is weight loss-induced muscle mass loss clinically relevant? JAMA. 2024;332(1):9-10. [Debate commentary on clinical significance of lean mass loss in GLP-1 trials.]